Firefly Neuroscience, Inc. (NASDAQ:AIFF) Short Interest Update

Firefly Neuroscience, Inc. (NASDAQ:AIFF) saw a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,551,962 shares, an increase of 300.2% from the February 26th total of 387,780 shares. Based on an average daily trading volume, of 45,958,225 shares, the days-to-cover ratio is currently 0.0 days. Currently, 11.7% of the company’s shares are sold short.

Firefly Neuroscience Price Performance

Shares of Firefly Neuroscience stock opened at $1.68 on Thursday. Firefly Neuroscience has a 1-year low of $0.62 and a 1-year high of $4.58. The company has a market capitalization of $23.89 million, a PE ratio of -0.80 and a beta of 1.92. The business has a 50-day moving average of $1.17 and a 200-day moving average of $1.67.

Institutional Investors Weigh In On Firefly Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Firefly Neuroscience by 393.3% in the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Firefly Neuroscience during the fourth quarter worth approximately $53,000. Finally, Savvy Advisors Inc. acquired a new stake in shares of Firefly Neuroscience during the third quarter worth approximately $63,000. 4.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.